The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Download your free eBook

Rubella Virus-Like Particles: The New Candidate of Choice for Diagnosing and Preventing Rubella

  • Rubella virus is notoriously difficult to culture and extremely challenging – and therefore costly – to propagate at scale
  • Rubella Virus-Like Particles (VLPs) hold huge potential as a scalable, cost-effective route to immunization for vaccine developers, and as a novel platform for rubella research and diagnostics
  • VLPs can be synthesized much faster, taking just 12 to 14 weeks in a variety of expression systems, compared to 24 to 32 weeks for cultivation and deactivation of whole virus particles
  • Replacing native rubella products on the market with recombinant VLPs may be the solution that researchers need to meet the World Health Organization’s goal of achieving a world free from measles and rubella infections by 2030

Simply fill out the form below to get your copy.